{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:37:48Z","timestamp":1782207468225,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The net benefits of new hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>) direct\u2010acting antiviral drugs (<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>) in patients with cryoglobulinaemia vasculitis (CryoVas) are unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To analyse the effectiveness and cost of all treatments used for <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010CryoVas in the <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> vs pre\u2010<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> era.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A chart review of all <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010CryoVas patients who received antivirals from 1993 to 2016 in a tertiary centre was performed. Treatment effectiveness was analysed for clinical, immunological and virological responses. Cost analyses included anti\u2010<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> treatments, non\u2010antiviral drugs, plasmapheresis, dialysis and hospitalizations. We compared main data in the pre\u2010<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> vs <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>About 201 <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\u2010CryoVas patients were included (women, 53.2%; mean age, 59.2\u00a0years; Metavir score F3\u2010F4, 36.7%; genotype 1, 64.2%). Patients in the <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> era (n=27) compared to those in the pre\u2010<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> era (n=174) showed higher rates of clinical (96.3% vs. 78.6%), immunological (89.5% vs. 77.1%), and sustained virological response (75.0% vs. 42.8%). Death rate was 14.8% vs. 24.4% respectively. In the <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> compared to pre\u2010<jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> era, mean cost of anti\u2010<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> drugs increased from 11\u00a0855 to 57\u00a0632 \u20ac while mean CryoVas\u2010related cost decreased for both hospitalizations (from 33\u00a0510 to 21\u00a0347\u20ac) and non\u2010antiviral treatments (from 17\u00a0347 to 11\u00a0397\u20ac).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Improved antiviral efficacy of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> drugs in the <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content> era led to increased clinical and immunological efficacy and a lower death rate. Use of <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>s was associated to higher costs for <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> drugs while costs related to both hospitalizations and non\u2010antiviral treatments decreased.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.13465","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T13:12:50Z","timestamp":1493817170000},"page":"1805-1813","source":"Crossref","is-referenced-by-count":27,"title":["Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon\u2010based to direct\u2010acting antivirals era"],"prefix":"10.1111","volume":"37","author":[{"given":"Patrice","family":"Cacoub","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9s UPMC Univ Paris 06 UMR 7211  Paris France"},{"name":"Inflammation\u2010Immunopathology\u2010Biotherapy Department (DHU i2B)  Paris France"},{"name":"INSERM UMR_S 959  Paris France"},{"name":"CNRS FRE3632  Paris France"},{"name":"Department of Internal Medicine and Clinical Immunology AP\u2010HP Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vautier","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s UPMC Univ Paris 06 UMR 7211  Paris France"},{"name":"Inflammation\u2010Immunopathology\u2010Biotherapy Department (DHU i2B)  Paris France"},{"name":"INSERM UMR_S 959  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4638-1238","authenticated-orcid":false,"given":"Anne Claire","family":"Desbois","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s UPMC Univ Paris 06 UMR 7211  Paris France"},{"name":"Inflammation\u2010Immunopathology\u2010Biotherapy Department (DHU i2B)  Paris France"},{"name":"INSERM UMR_S 959  Paris France"},{"name":"CNRS FRE3632  Paris France"},{"name":"Department of Internal Medicine and Clinical Immunology AP\u2010HP Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lafuma","sequence":"additional","affiliation":[{"name":"CEMKA Outcomes Research Epidemiology  Bourg la Reine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s UPMC Univ Paris 06 UMR 7211  Paris France"},{"name":"Inflammation\u2010Immunopathology\u2010Biotherapy Department (DHU i2B)  Paris France"},{"name":"INSERM UMR_S 959  Paris France"},{"name":"CNRS FRE3632  Paris France"},{"name":"Department of Internal Medicine and Clinical Immunology AP\u2010HP Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,29]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"OMS.H\u00e9patite C [Internet].WHO. Available at:http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/fr\/. Accessed March 18 2017."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936115585942"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.247"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-016-0410-9"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.02.017"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208642"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30319"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.05.017"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.015"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208339"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.2.614-616.2006"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/38.6.798"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(74)90852-3"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840200104"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28753"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403173301104"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22168"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28297"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27623"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1021660"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34331"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34322"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248518"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-245878"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.25000"},{"key":"e_1_2_10_32_1","unstructured":"Les d\u00e9penses de sant\u00e9 en 2014 \u2010 R\u00e9sultats des Comptes de la sant\u00e9 \u2010 Comptes nationaux de la sant\u00e9 \u2010 Minist\u00e8re des Affaires sociales et de la Sant\u00e9 [Internet]. [cit\u00e9 23 ao\u00fbt2016]. Available at:http:\/\/drees.social-sante.gouv.fr\/etudes-et-statistiques\/publications\/recueils-ouvrages-et-rapports\/recueils-annuels\/comptes-nationaux-de-la-sante\/article\/les-depenses-de-sante-en-2014-resultats-des-comptes-de-la-sante. Accessed August 23 2016."},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.039"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27600"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150479"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.13465","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.13465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:42:33Z","timestamp":1695552153000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,29]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/liv.13465"],"URL":"https:\/\/doi.org\/10.1111\/liv.13465","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,29]]}}}